News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
UNITED LAB, Novo Nordisk Sign Exclusive Licensing Agreement for UBT251
UNITED LAB (03933.HK) announced that it had entered into an exclusive licensing agreement with its wholly-owned subsidiary United Biotechnology and Novo Nordisk for UBT251, a tripl...
Reset
Send
The window will close in 5 seconds
UNITED LAB, Novo Nordisk Sign Exclusive Licensing Agreement for UBT251
Close
Recommend
15
Positive
14
Negative
6
 
SHORT SELL
 
STOCK INFO

UNITED LAB (03933.HK)  -0.350 (-2.076%)    Short selling $7.48M; Ratio 6.470%   announced that it had entered into an exclusive licensing agreement with its wholly-owned subsidiary United Biotechnology and Novo Nordisk for UBT251, a triple agonist of the receptors of GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes and other diseases.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-08-22 12:25.)

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.